Everest Medicines Limited

Everest Medicines Announces Positive First-in-Human Data for Personalized mRNA Cancer Vaccine EVM16 at AACR 2026

HONG KONG, Apr 22, 2026 - (ACN Newswire) - Apr 20, Everest Medicines announced that the first-in-human (FIH) clinical trial data of EVM16, a proprietary personalized mRNA cancer vaccine, were presented at the 2026 American Association for Cancer Research Annual Meeting (AACR 2026). The data include ...

22.04.2026 | Pharma